Steady-state plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone (9-OH) in 18 patients treated with risperidone and CYP2D6 genotype (n = 11)
| Patient No. | Gender | Age | CYP2D6 Genotype | Dose | Plasma concentration (nmol/l) | Enantiomeric Ratio (+)-9-OH/(−)-9-OH | ||
|---|---|---|---|---|---|---|---|---|
| Risperidone | (+)-9-OH | (−)-9-OH | ||||||
| years | mg/day | |||||||
| 1 | M | 52 | *1/*1 | 6 | 53.5 | 125.8 | 31.0 | 4.07 |
| 2 | F | 49 | *1/*1 | 6 | 60.8 | 253.3 | 76.6 | 3.31 |
| 3 | M | 49 | *1/*1 | 6 | 17.0 | 109.6 | 26.1 | 4.19 |
| 4 | F | 31 | *1/*4 | 6 | 31.6 | 231.3 | 75.2 | 3.08 |
| 5 | F | 46 | *1/*4 | 6 | 87.5 | 130.3 | 52.2 | 2.50 |
| 6 | M | 46 | *1/*4 | 6 | 14.6 | 97.4 | 54.7 | 1.78 |
| 7 | M | 39 | *1/*5 | 6 | 141.0 | 251.0 | 88.3 | 2.84 |
| 8 | M | 27 | *1/*1 | 6 | 72.9 | 137.3 | 54.6 | 2.51 |
| 9 | M | 30 | *1/*4 | 6 | 70.5 | 64.9 | 42.7 | 1.52 |
| 10 | M | 31 | *1/*4 | 6 | 55.9 | 104.1 | 31.7 | 3.29 |
| 11 | M | 60 | *4/*5 | 4 | 68.0 | N.D. | 58.5 | N.C. |
| 12 | M | 49 | 6 | 19.5 | 177.2 | 68.5 | 2.58 | |
| 13 | F | 37 | 6 | 14.6 | 73.4 | 50.6 | 1.45 | |
| 14 | M | 30 | 3 | 4.5 | 83.8 | 61.4 | 1.36 | |
| 15 | F | 48 | 9 | 34.2 | 385.6 | 129.2 | 2.98 | |
| 16 | M | 31 | *1/*4 | 4 | 9.8 | <25.0 | <25.0 | N.C. |
| 17 | F | 39 | 4 | 14.6 | 177.2 | 59.1 | 3.00 | |
| 18 | M | 55 | 8 | 126.9 | 111.3 | 45.4 | 2.45 | |
N.D., not detected; N.C., not calculated; M, male; F, female.